검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD30+ CAR T-cells |
Overview Company | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Relapsed or Refractory Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Toxicology CRS | Reported |
Clinical Result source | ClinicalTrials.gov NCT03049449 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD30+ CAR T-cells |
Overview Company | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Relapsed or Refractory Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results |
MoA Biomarker | CD19 CAR T-cells produce high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30 + lymphomas.. INTRODUCTION: Although CD30-directed chimeric antigen receptor (CAR)-T cell therapy has demonstrated antitumor activity in CD30+ lymphomas, its therapeutic efficacy remains suboptimal. We therefore conducted a prospective, phase II, single-arm, multicenter clinical trial (ChiCTR-2100046763) to eva… |
Toxicology CRS | Reported |
Clinical Result source | ClinicalTrials.gov NCT03049449 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교